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Background: Risk factors of bleeding and recurrent ischemic events after acute coronary syndrome (ACS) often overlap. Whether 
the distribution and management of these complications vary by sex remains unknown.
Methods: ACS hospitalizations in the United Kingdom between 2010 and 2017 were retrospectively analyzed, stratified by sex and 
bleeding-ischaemic risk combination (using CRUSADE and GRACE scores). Regression analyses were performed to examine the 
association between risk-groups and receipt of percutaneous coronary intervention (PCI) and dual antiplatelet therapy (DAPT) on 
discharge, as well as in-hospital clinical outcomes.
Results: Out of 584,360 patients, a third of males (32.3%) and females (32.6%) were in the dual high bleeding-ischemic risk group. 
Dual high-risk patients of both sexes were less likely to receive PCI and DAPT, with a significant increase in odds of MACE, all-
cause and cardiac mortality, and bleeding (see figure), with the greatest difference between sexes observed in the dual-high risk 
group in which females were less likely to receive guideline-recommended therapy (PCI and DAPT) and more likely to experience 
adverse outcomes.
Conclusion: ACS patients with dual high bleeding-ischemic risk are less likely to receive guideline-recommended therapy and 
experience significantly worse outcomes, especially in females. Novel strategies are needed to effectively manage this highly 
prevalent and complex patient group and address the under-treatment of females. 
